Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.

Literature DB >> 32720828

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.

Ahmed Sawas¹, Helen Ma¹, John Kuruvilla², Jennifer K Lue¹, Changchun Deng¹, Enrica Marchi¹, Francesca Montanari¹, Bin Cheng¹, Kerry J Savage³, Diego Villa³, Michael Crump², Joseph M Connors³, Owen A O'Connor⁴.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2020 PMID： 32720828 DOI： 10.1080/10428194.2020.1795161

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

Keyword Cloud
Cited

× No keyword cloud information.

1 in total

1. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.

Authors: Marina Moretti; Anna Marina Liberati; Luigi Rigacci; Benedetta Puccini; Alessandro Pulsoni; Guido Gini; Piero Galieni; Alberto Fabbri; Maria Cantonetti; Vincenzo Pavone; Silvia Bolis; Barbara Botto; Daniela Renzi; Lorenzo Falchi
Journal: Clin Lymphoma Myeloma Leuk Date: 2021-09-29

1 in total